On Tuesday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) opened higher 1.01% from the last session ,before settling in for the closing price of $46.44. Price fluctuations for CRNX have ranged from $15.50 to $49.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 64.83%. Company’s average yearly earnings per share was noted 13.21% at the time writing. With a float of $71.18 million, this company’s outstanding shares have now reached $77.93 million.
Considering the fact that the conglomerate employs 290 people, you should pay attention to its efficiency factor.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Crinetics Pharmaceuticals Inc is 8.67%, while institutional ownership is 89.34%. The most recent insider transaction that took place on Apr 04 ’24, was worth 2,013,561. In this transaction President & CEO of this company sold 40,951 shares at a rate of $49.17, taking the stock ownership to the 237,835 shares. Before that another transaction happened on Mar 28 ’24, when Company’s Director sold 17,500 for $46.38, making the entire transaction worth $811,650. This insider now owns 6,000 shares in total.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/30/2023, the company posted -$0.9 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.86) by -$0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.21% per share during the next fiscal year.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Check out the current performance indicators for Crinetics Pharmaceuticals Inc (CRNX). In the past quarter, the stock posted a quick ratio of 13.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.70, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -3.54 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Compared to the last year’s volume of 0.8 million, its volume of 1.21 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 61.92%. Additionally, its Average True Range was 2.54.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 87.88%, which indicates a significant increase from 63.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.82% in the past 14 days, which was lower than the 54.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.15, while its 200-day Moving Average is $30.27. Nevertheless, the first resistance level for the watch stands at $47.42 in the near term. At $47.94, the stock is likely to face the second major resistance level. The third major resistance level sits at $48.65. If the price goes on to break the first support level at $46.20, it is likely to go to the next support level at $45.49. Now, if the price goes above the second support level, the third support stands at $44.97.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
There are currently 69,600K shares outstanding in the company with a market cap of 3.66 billion. Presently, the company’s annual sales total 4,010 K according to its annual income of -214,530 K. Last quarter, the company’s sales amounted to 350 K and its income totaled -57,460 K.
